Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus INDIUM IN 111 PENTETREOTIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus INDIUM IN 111 PENTETREOTIDE KIT.
CERETEC vs INDIUM IN-111 PENTETREOTIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical